Answers are grounded in this paper and cite their sources.
The study by Hagström et al. provide important insights into our understanding of the natural history of lean NAFLD. Even though lean patients with NAFLD have no increased risk of mortality (HR 1.04), the rates of progression to severe liver disease (most notably cirrhosis) highlight that lean NAFLD is not a simple, benign condition. Further study of these “outliers” in the global NAFLD epidemic may provide important insights into the putative mechanisms linking hepatic steatosis to a myriad of clinical outcomes, including liver, cardiovascular and cancer‐related morbidity and mortality in NAFLD.
No takes yet. Share an insight, caveat, or question.
VanWagner et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: